About us

NTT BIOPHARMA

Nano Targeting and Therapy (NTT) Biopharma Inc. is a cutting-edge biotechnology company pioneering the use of mesoporous silica nanoparticles (MSNs) for the precise and efficient delivery of therapeutic molecules. Our vision is to tackle critical challenges and deliver improved solutions in drug delivery to address unmet medical needs in the fields of brain diseases, ocular and retinal diseases, oncology, and gene therapy. We are committed to create a new generation of effective nanomedicines that optimize therapies across a broad range of diseases.

Technology

MESOPOROUS SILICA NANOPARTICLE AS A DRUG-DELIVERY PLATFORM FOR OVERCOMING THE HURDLES OF DRUG DELIVERY

NTT’s proprietary mesoporous silica nanoparticles (MSNs) provide a highly tunable drug delivery platform with superior loading capacity, targeted delivery, and improved therapeutic efficacy with reduced side effects. This platform is designed to address key challenges in drug delivery and unlock new treatment possibilities.
NTT is advancing its MSN technology across a range of high-impact medical applications to offer a promising approach for unmet medical needs.

Pipeline

NTT-001 (Primary and Metastatic Brain Cancer)

The blood-brain barrier (BBB) blocks over 95% of drugs, posing a critical obstacle to brain disease treatment. NTT’s MSN technology provides a promising delivery platform that penetrates the BBB and selectively delivers therapeutics to diseased regions, enabling effective treatment of primary and metastatic brain cancers.

NTT-002 (Highly Metastatic Colorectal Cancer)

Colorectal cancer is highly metastatic and ranks as the second most common cancer globally, and the most prevalent in many East Asian countries. NTT-002 is engineered to suppress both primary tumor growth and metastasis, offering a promising approach for the treatment of aggressive cancers.

Ocular Disease (Eyedrop Nanoformulation)

Posterior segment diseases, include age-related macular degeneration, Leber Hereditary Optic Neuropathy, etc., are leading causes of vision impairment and blindness. However, the blood-ocular barriers prevent most drugs from reaching the posterior segment of the eye. Our MSN eyedrop nanoformulation provides a non-invasive alternative to intravitreal injection, the current standard for retinal drug delivery.